COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

Alliance-A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with CLL

Protocol No
ALLIANCE-A041702-CLL
Principal Investigator
Sameem Abedin
Phase
III
Summary
This study is being done to answer the following questions: 1. Is adding a new anti-cancer drug (venetoclax) to the usual treatment (ibrutinib plus obinutuzumab) better, the same as, or worse than the usual treatment alone for untreated older patients with CLL? 2. Can patients who have no detectable CLL after a year of receiving the usual treatment plus the new anti-cancer drug discontinue therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for chronic lymphocytic leukemia. The usual approach is defined as care most people get for chronic lymphocytic leukemia.
Description
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Older Patients With Untreated Chronic Lymphocytic Leukemia
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL